Literature DB >> 12760459

Methylprednisolone in acute spinal cord injuries.

P A O'Connor1, O McCormack, C Gavin, R Dungan, C Kirke, D McCormack, J O'Byrne, M Stephens, F McManus, M Walsh.   

Abstract

BACKGROUND: Methylprednisolone is the only neuroprotective therapy advocated in acute non-penetrating spinal cord injury. Trials indicate improved neurological outcome following early administration of a high dose regime. The National Spinal Injuries Unit (NSIU) has promoted this regime by a simple laminated poster sent to all Irish A&E departments. AIM: To assess the use of methylprednisolone in patients with spinal cord injuries.
METHODS: A retrospective audit of patient data for all patients admitted with traumatic neurological impairment over a 12-month period.
RESULTS: One hundred ninety-six patients were admitted during the study period, 28 (14%) received intravenous methylprednisolone of which six had clear records documenting compliance. One patient received both dexamethasone and methylprednisolone in high doses and three had incorrect bolus dosages administered. Six patients received methylprednisolone infusion longer than the protocol, while five patients were given infusions shorter than recommended. Three patients were admitted to the unit that could have received the steroid regime at the point of transfer.
CONCLUSIONS: There was poor documentation of prescription orders and timing of administration. Only six patients had clear documentation allowing confirmation of adherence to the protocol of the National Acute Spinal Cord Injury Study (NASCIS) III trial.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12760459     DOI: 10.1007/bf02914781

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  11 in total

1.  Editorial: recommendations regarding the use of methylprednisolone in acute spinal cord injury: making sense out of the controversy.

Authors:  M G Fehlings
Journal:  Spine (Phila Pa 1976)       Date:  2001-12-15       Impact factor: 3.468

2.  The Sygen multicenter acute spinal cord injury study.

Authors:  F H Geisler; W P Coleman; G Grieco; D Poonian
Journal:  Spine (Phila Pa 1976)       Date:  2001-12-15       Impact factor: 3.468

3.  Summary statement: the Sygen(GM-1 ganglioside) clinical trial in acute spinal cord injury.

Authors:  M G Fehlings; M B Bracken
Journal:  Spine (Phila Pa 1976)       Date:  2001-12-15       Impact factor: 3.468

4.  Methylprednisolone for acute spinal cord injury: an inappropriate standard of care.

Authors:  R J Hurlbert
Journal:  J Neurosurg       Date:  2000-07       Impact factor: 5.115

5.  A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury.

Authors:  W P Coleman; D Benzel; D W Cahill; T Ducker; F Geisler; B Green; M R Gropper; J Goffin; P W Madsen; D J Maiman; S L Ondra; M Rosner; R C Sasso; G R Trost; S Zeidman
Journal:  J Spinal Disord       Date:  2000-06

6.  Efficacy of methylprednisolone in acute spinal cord injury.

Authors:  M B Bracken; W F Collins; D F Freeman; M J Shepard; F W Wagner; R M Silten; K G Hellenbrand; J Ransohoff; W E Hunt; P L Perot
Journal:  JAMA       Date:  1984-01-06       Impact factor: 56.272

7.  Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study.

Authors:  M B Bracken; M J Shepard; T R Holford; L Leo-Summers; E F Aldrich; M Fazl; M Fehlings; D L Herr; P W Hitchon; L F Marshall; R P Nockels; V Pascale; P L Perot; J Piepmeier; V K Sonntag; F Wagner; J E Wilberger; H R Winn; W Young
Journal:  JAMA       Date:  1997-05-28       Impact factor: 56.272

8.  Acute management of spinal cord injury.

Authors:  R B Delamarter; J Coyle
Journal:  J Am Acad Orthop Surg       Date:  1999 May-Jun       Impact factor: 3.020

9.  A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study.

Authors:  M B Bracken; M J Shepard; W F Collins; T R Holford; W Young; D S Baskin; H M Eisenberg; E Flamm; L Leo-Summers; J Maroon
Journal:  N Engl J Med       Date:  1990-05-17       Impact factor: 91.245

10.  Methylprednisolone and neurological function 1 year after spinal cord injury. Results of the National Acute Spinal Cord Injury Study.

Authors:  M B Bracken; M J Shepard; K G Hellenbrand; W F Collins; L S Leo; D F Freeman; F C Wagner; E S Flamm; H M Eisenberg; J H Goodman
Journal:  J Neurosurg       Date:  1985-11       Impact factor: 5.115

View more
  1 in total

1.  High dose methylprednisolone in the immediate management of acute, blunt spinal cord injury: what is the current practice in emergency departments, spinal units, and neurosurgical units in the UK?

Authors:  A E Frampton; C A Eynon
Journal:  Emerg Med J       Date:  2006-07       Impact factor: 2.740

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.